drugset / Trial / NCT01473758

Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT01473758

Phase 2 Terminated 81 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential benefit of roflumilast on severity and recovery periods of acute COPD exacerbations will be assessed using patient diaries and questionnaires.

Timeline

Start
2012-02
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Roflumilast Small molecule 500 ug Oral